These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2384664)

  • 1. The autocrine production of transforming growth factor-beta 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA.
    Lucas C; Bald LN; Fendly BM; Mora-Worms M; Figari IS; Patzer EJ; Palladino MA
    J Immunol; 1990 Sep; 145(5):1415-22. PubMed ID: 2384664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of growth factors on the antiproliferative activity of tumor necrosis factors.
    Sugarman BJ; Lewis GD; Eessalu TE; Aggarwal BB; Shepard HM
    Cancer Res; 1987 Feb; 47(3):780-6. PubMed ID: 3802082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification.
    Dasch JR; Pace DR; Waegell W; Inenaga D; Ellingsworth L
    J Immunol; 1989 Mar; 142(5):1536-41. PubMed ID: 2537357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.
    Espevik T; Figari IS; Ranges GE; Palladino MA
    J Immunol; 1988 Apr; 140(7):2312-6. PubMed ID: 3280680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
    Kasid A; Bell GI; Director EP
    J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor-beta 1 is required for secretion of IgG of all subclasses by LPS-activated murine B cells in vitro.
    Snapper CM; Waegell W; Beernink H; Dasch JR
    J Immunol; 1993 Nov; 151(9):4625-36. PubMed ID: 8409423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-1 alpha induces expression of active transforming growth factor-beta in nonproliferating T cells via a post-transcriptional mechanism.
    Bristol LA; Ruscetti FW; Brody DT; Durum SK
    J Immunol; 1990 Dec; 145(12):4108-14. PubMed ID: 2175324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The first stage of transforming growth factor beta1 activation is release of the large latent complex from the extracellular matrix of growth plate chondrocytes by matrix vesicle stromelysin-1 (MMP-3).
    Maeda S; Dean DD; Gomez R; Schwartz Z; Boyan BD
    Calcif Tissue Int; 2002 Jan; 70(1):54-65. PubMed ID: 11907708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further studies of the role of transforming growth factor-beta in human B cell function.
    Kehrl JH; Taylor AS; Delsing GA; Roberts AB; Sporn MB; Fauci AS
    J Immunol; 1989 Sep; 143(6):1868-74. PubMed ID: 2550546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF-beta: a possible autocrine immune regulator.
    Lucas C; Wallick S; Fendly BM; Figari I; Palladino MA
    Ciba Found Symp; 1991; 157():98-108; discussion 108-14. PubMed ID: 2070686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opposing effects of TGF-beta 2 on the Th1 cell development of naive CD4+ T cells isolated from different mouse strains.
    Hoehn P; Goedert S; Germann T; Koelsch S; Jin S; Palm N; Ruede E; Schmitt E
    J Immunol; 1995 Oct; 155(8):3788-93. PubMed ID: 7561083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies to human recombinant interleukin 1 (IL 1)beta: quantitation of IL 1 beta and inhibition of biological activity.
    Kenney JS; Masada MP; Eugui EM; Delustro BM; Mulkins MA; Allison AC
    J Immunol; 1987 Jun; 138(12):4236-42. PubMed ID: 2438338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and characterization of monoclonal antibodies specific for human transforming growth factor alpha.
    Sorvillo JM; McCormack ES; Yanez L; Valenzuela D; Reynolds FH
    Oncogene; 1990 Mar; 5(3):377-86. PubMed ID: 1690379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human hybridoma-derived suppressor factor 160 and transforming growth factor-beta are different molecules.
    Fox FE; Oleszak EL; Chen PF; Platsoucas CD
    Lymphokine Cytokine Res; 1992 Dec; 11(6):307-15. PubMed ID: 1477184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Particular types of tumor cells have the capacity to convert transforming growth factor beta from a latent to an active form.
    Takiuchi H; Tada T; Li XF; Ogata M; Ikeda T; Fujimoto S; Fujiwara H; Hamaoka T
    Cancer Res; 1992 Oct; 52(20):5641-6. PubMed ID: 1327512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
    Arteaga CL; Hurd SD; Winnier AR; Johnson MD; Fendly BM; Forbes JT
    J Clin Invest; 1993 Dec; 92(6):2569-76. PubMed ID: 7504687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanisms of enhanced accumulation of transferred LAK cells into tumor sites after chemotherapy].
    Kuramitsu Y
    Hokkaido Igaku Zasshi; 1995 May; 70(3):507-17. PubMed ID: 7590601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor-beta 1 enhances the generation of allospecific cytotoxic T lymphocytes.
    Kondo S; Isobe K; Ishiguro N; Nakashima I; Miura T
    Immunology; 1993 Jul; 79(3):459-64. PubMed ID: 8406573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the latent transforming growth factor beta complex in bone.
    Pfeilschifter J; Bonewald L; Mundy GR
    J Bone Miner Res; 1990 Jan; 5(1):49-58. PubMed ID: 2309578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
    Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
    J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.